Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 666 participants.

Also called NCT04968184

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 666 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04968184
  • EudraCT 2021-003636-88
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Bosnia & Herzegovina, Bulgaria, Canada, China, Croatia, Czechia, Georgia, Germany, Hong Kong SAR China, Hungary, Israel, Latvia, Lithuania, Malaysia, Poland, Serbia, South Africa, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04968184. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-05 (actual); primary completion 2024-01-30 (actual). Results posted on 2026-11-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
Acronym
Clarion-CKD
Condition
Chronic Kidney Diseases
Intervention (Drug)
Placebo
Intervention (Drug)
KBP-5074
Lead sponsor
Novo Nordisk A/S (class: industry)
Collaborator
KBP Biosciences (class: industry)

Record details

Record id
cardio:ct-nct04968184
Content hash
fb589957dfc67f37e2075915b49152790a38745d99d847f9a15bcb1d8f1a1e8e